SCARDA: Japan’s Big Hope To Change Its Vaccine R&D Ecosystem
$1bn Support Now Expanded
Japan's SCARDA is building networks with academia and industry to support new vaccine development, while offering support through funding and knowledge. But is that enough to overcome the shortcomings highlighted by the pandemic?
You may also be interested in...
Japan Kicks Off $366m Bioventure Support Program
A new state-supported scheme is to provide funding for R&D programs at Japanese bioventures, with up to JPY10bn available for each project. Eight selected VCs will fund one-third of the total, with the government to provide the rest.
Japan Lists Eight Infectious Diseases For Focused Vaccine Development
The list including eight types of diseases such as flu and coronavirus infection, smallpox will be sent to SCARDA to determine which domestic vaccine development projects by pharmaceutical firms are to be funded. Some participants at the Ministry of Health, Labour and Welfare’s discussion insisted on continuous monitoring.
SCARDA: Japan’s New Vaccine R&D Center With $1.6bn Budget – But Where's The Goal?
Japan has launched a new center to support vaccine and drug projects as a part of a larger scheme to tackle infectious disease. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects.